News
Entertainment
Science & Technology
Life
Culture & Art
Hobbies
News
Entertainment
Science & Technology
Culture & Art
Hobbies
Discover Latest #European Investment Bank News, Articles and Videos with Contenting
The European Investment Bank (EIB) is the largest multilateral lender and the long-term lending institution of the European Union (EU). Founded in 1958, the EIB is one of the world’s largest public lending institutions. The EIB provides financing for projects that support the economic development of the European Union and its member states. The EIB finances projects that are designed to promote European economic growth, reduce unemployment, and improve social and environmental standards. In addition, the EIB provides financial support to small and medium-sized businesses. The EIB also invests in projects that promote research, innovation, and education. The EIB is managed by the European Commission and is part of the EU’s budget. The EIB works closely with other financial institutions and national governments to support sustainable development. The EIB’s activities are supervised and regulated by the European Parliament and the European Central Bank. The EIB publishes news and articles regularly on its website and through its social media channels. These articles and videos provide information on the EIB’s activities, projects, and investment opportunities. They also provide insights into the European economy and the EIB’s role in it. In addition
Eleva administers first dose of its Factor H biological treatment in C3-Glomerulopathy to healthy volunteers - ForexTV
First-in-human administration of CPV-104 marks a major step in drug development for the company’s lead compound (Factor H) and in bringing a new medication to patients Freiburg im Breisgau, Germany, July 7, 2025 – Eleva, a pioneer in discovering and developing previously inaccessible biologics based on a breakthrough technology platform, announced today the first dosing in its Phase 1 clinical study investigating the company’s Factor H (CPV-104) program in C3-Glomerulopathy (C3G). In the first part of the clinical study, Eleva is investigating single-ascending doses of CPV-104 in healthy volunteers. “Today’s news marks our second proprietary program advancing into clinical trials, which is a great achievement from an organizational standpoint,” commented Björn Cochlovius, Ph.D., Chief Executive Officer of Eleva. “Our Factor H biological therapy platform continues to evolve, gaining visibility among clinicians and potential partners alike. We will continue to add value to this program in C3G as our initial focus, dry AMD as a second indication, and potentially several others down the road, while creating the best infrastructure for its successful clinical development.” “We are thrilled to advance our Factor H molecule into a first-in-human study to evaluate the safety and tolerability and pharmacokinetics for further clinical studies. I like to thank all team members at Eleva and our clinical partners for their continued efforts and commitment to meet this milestone,” commented Dr. Martin Bauer, Chief Medical Officer of Eleva. C3G represents a rare renal disease caused by the abnormal regulation of the complement system, particularly the alternative pathway of the complement cascade, a central part of the body’s immune defense. Naturally occurring complement regulators such as Factor H offer a therapeutic approach to help restore balance within the complement system and have shown therapeutic potential in a range of indications. Preclinical data sets were recently published in Frontiers in Immunology and underscored Factor H (CPV-104)’s ability to act as a functional analogue of human Factor H, support normalization of serum C3 levels and lead to a rapid degradation of C3 deposits in the kidney. The program has received the Orphan Drug Designation in the European Union for C3G and is also being pursued by Eleva in dry AMD as a second indication. ABOUT ELEVAEleva is a clinical-stage biopharmaceutical company discovering and developing previously inaccessible biological therapeutics. Eleva’s disruptive moss-based technology platform enables GMP-scale manufacturing of human proteins with tremendous therapeutic potential that other platforms cannot achieve. The company’s proprietary pipeline includes candidates for complement disorders and enzyme replacement therapies. The lead program, Factor H (CPV-104), a recombinant human complement Factor H, has entered a Phase 1/2 clinical studies to treat C3 Glomerulopathy (C3G). An intravitreal formulation of the candidate is in late preclinical development to treat dry AMD. The company’s aGal (RPV-001) program has completed a positive Phase 1b single-dose clinical trial to treat Fabry disease. MEDIA CONTACTS Fabienne ZeitterDirector Marketingpr@elevabiologics.comPhone: +49 761 470 99 0 Valency CommunicationsMario Brkuljmbrkulj@valencycomms.euPhone: +49 160 9352 9951 INVESTOR CONTACT Cohesion BureauGiovanni Ca’ Zorzigiovanni.cazorzi@cohesionbureau.comPhone: +33 7 84 67 07 27 Attachment 250707_Eleva_1st_Dosing_FactorH_ENG
Overcoming the Traps that Prevent Growth in Uncertain Times
How can executives create a resilient growth strategy when there is little to no clarity about what the future holds? Even seasoned leaders will need to avoid the traps that keep organizations from pursuing and achieving growth in times like these. This playbook helps executives develop a strategy that is both feasible and durable.
Inside the Billionaire Diversification Playbook of 2025 - Finance Monthly | Personal Finance. Money. Investing
In 2025, the rules of wealth management have changed. While billionaires used to rely on traditional assets like real estate, stocks, and gold to preserve their fortunes, the new era of diversification includes cutting-edge tools like crypto wallets and decentralized finance (DeFi) platforms. These innovations have reshaped how the ultra-wealthy…
A €30 million scheme: how did the Subbotins' firms withdraw funds from the Ministry of Finance and the EBRD from Megabank?
A story that undermines confidence in the Ukrainian banking system: Who is behind the collapse of Megabank? The bank is still under investigation for the possible embezzlement of about 30 million euros received from the Ministry of Finance and the European Investment Bank (EIB).
EvenUp Announces AI Playbooks and Voice Agent to Redefine Case Analysis and Client Communication - Fintech News
The category leader in AI for personal injury expands its platform with two new products while continuing its rapid pace of innovation with upgrades to the AI Drafts Suite. SAN FRANCISCO–(BUSINESS WIRE)–#AI—EvenUp, the category leader in AI for personal injury (PI) law, today announced two new products that push the boundaries of legal technology: AI […]
Building a Business That Lasts: Why Planning Beats Hype - TechBullion
You’ve seen it before. A startup launches with a flashy website, tons of buzz on social media, maybe even a press feature or two. For a few months, it’s all noise and momentum. And then—nothing. It fades, like it never existed. That’s because hype wears off fast. What doesn’t fade is planning. Businesses that last […]
EvenUp Announces AI Playbooks and Voice Agent to Redefine Case Analysis and Client Communication EvenUp Announces AI Playbooks and Voice Agent to Redefine Case Analysis and Client Communication
Discover the latest fintech news with Fintech Inshorts, Explore banking trends, financial innovation. expert analyses, blogs and fintech advancements.
How Pop Mart Won Young Customers in a Fragmented Attention Economy
To win young customers who grow up in today’s fragmented attention economy, leaders need to deploy strategies specifically tailored to the emotional and identity needs of these individuals. Analysis of Pop Mart—a Chinese brand listed on the Hong Kong stock market known for its globally popular Labubu dolls—offers valuable insights. First, it uses real-time consumer data to inform product strategies, adjust design, marketing and supply chain decisions, identifying the right innovations and making profits in an agile manner. Second, the brand assesses and manages to meet the digital natives’ psychological longing for individuality and community. Spotting and enhancing touchpoints with their young customers helps firms to deepen the brand affinity among this audience. Then, Pop Mart’s cultivation of unique brand language in online conservations further helps its communication with the digital native generation, enhancing belonging and loyalty. Companies across a wide range of industries, not just those in consumer goods and services, can learn from Pop Mart’s playbook to build adaptive and data-informed brand strategies that support agile and cost-effective growth.